Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Describe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan in
cancer patients with advanced solid tumors with UGT1A1 6/6 and 6/7 genotypes.